Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01627379 | Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer(POWER) | terminated | Phase 3 | 300 | AIO-Studien-gGmbHOTHER | 1 | Mar 2, 2018 | clinicaltrials |
| NCT01002248 | Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients | terminated | Phase 3 | 135 | AEterna ZentarisINDUSTRY | 9 | Feb 9, 2018 |
| NCT01264874 | MelaViD: A Trial on Vitamin D Supplementation for Resected Stage II Melanoma Patients(MelaViD) | terminated | Phase 3 | 150 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01683864 | Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer(HIPECStomach) | terminated | Phase 2 / Phase 3 | 3 | University Hospital TuebingenOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT01604005 | PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma(PIT) | terminated | Phase 3 | 375 | Brynn ChappellOTHER | 1 | Jan 29, 2018 | clinicaltrials |
| NCT02134015 | Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)(HER3-Lung) | terminated | Phase 3 | 145 | Daiichi SankyoINDUSTRY | 10 | Jan 23, 2018 | clinicaltrials |
| NCT02326285 | Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB(NeoIntercal) | terminated | Phase 2 / Phase 3 | 1 | AIO-Studien-gGmbHOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT00004874 | Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma | terminated | Phase 3 | 31 | University of NebraskaOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00562965 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 14 | Jan 9, 2018 | clinicaltrials |
| NCT00176839 | Stem Cell Transplantation for Hematological Malignancies | terminated | Phase 2 / Phase 3 | 11 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00574080 | UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide | terminated | Phase 3 | 20 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00657553 | Preemptive Strike With Bortezomib in Multiple Myeloma Patients(2007-77) | terminated | Phase 3 | 10 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01310803 | Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder | terminated | Phase 3 | 1 | Endo USA Inc., a Keenova Therapeutics CompanyINDUSTRY | 1 | Oct 5, 2017 | clinicaltrials |
| NCT00324987 | Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor(S0502) | terminated | Phase 3 | 12 | National Cancer Institute (NCI)NIH | 2 | Sep 14, 2017 | clinicaltrials |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | terminated | Phase 3 | 486 | Asan Medical CenterOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01200992 | Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer(EMBARC-RF) | terminated | Phase 3 | 84 | Bioniche Life Sciences Inc.INDUSTRY | 6 | Aug 24, 2017 | clinicaltrials |
| NCT02049151 | Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer(START2) | terminated | Phase 3 | 35 | EMD SeronoINDUSTRY | 2 | Aug 23, 2017 | clinicaltrials |
| NCT02655068 | Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer | terminated | Phase 3 | 38 | University of PittsburghOTHER | 1 | Jul 31, 2017 | clinicaltrials |
| NCT00714259 | Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies | terminated | Phase 2 / Phase 3 | 5 | University of Alabama at BirminghamOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00324324 | Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant | terminated | Phase 3 | 240 | OHSU Knight Cancer InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT01504308 | Sonalleve Fibroid Ablation Pivotal Clinical Trial for MR-HIFU of Uterine Fibroids(SOFIA) | terminated | Phase 2 / Phase 3 | 49 | Philips HealthcareINDUSTRY | 3 | Apr 5, 2017 | clinicaltrials |
| NCT00526643 | CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC Patients(CAPPA-2) | terminated | Phase 3 | 57 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | terminated | Phase 3 | 35 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT01319669 | Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy | terminated | Phase 2 / Phase 3 | 11 | Chinese Society of Lung CancerOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis(CICLODECH) | terminated | Phase 3 | 3 | Hospital Israelita Albert EinsteinOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00841945 | Treatment of Aggressive Localized Lymphoma | terminated | Phase 3 | 334 | French Innovative Leukemia OrganisationOTHER | 1 | Feb 23, 2017 | clinicaltrials |
| NCT02417129 | BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma | terminated | Phase 3 | 2 | Boehringer IngelheimINDUSTRY | 6 | Jan 30, 2017 | clinicaltrials |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | terminated | Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02213744 | MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients(HERMIONE) | terminated | Phase 2 / Phase 3 | 113 | Merrimack PharmaceuticalsINDUSTRY | 9 | Jan 6, 2017 | clinicaltrials |
| NCT01383148 | Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer(TIME) | terminated | Phase 2 / Phase 3 | 222 | TransgeneINDUSTRY | 10 | Jan 5, 2017 | clinicaltrials |
| NCT01377376 | A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib(ATTENTION) | terminated | Phase 3 | — | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Dec 7, 2016 | clinicaltrials |
| NCT01507467 | IAEA-HypoX. Accelerated Radiotherapy With or Without Nimorazole in Squamous Cell Carcinoma of the Head and Neck(IAEA-HypoX) | terminated | Phase 3 | 104 | Danish Head and Neck Cancer GroupNETWORK | 4 | Nov 25, 2016 | clinicaltrials |
| NCT01283763 | Topical Imiquimod Versus Conization to Treat Cervical Intraepithelial Neoplasia(ITIC2) | terminated | Phase 3 | 95 | Medical University of ViennaOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT01015443 | Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population(INSPIRE) | terminated | Phase 3 | 285 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 5 | Oct 26, 2016 | clinicaltrials |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | terminated | Phase 3 | 83 | German CLL Study GroupOTHER | 0 | Sep 26, 2016 | clinicaltrials |
| NCT00190554 | A Trial of Chemotherapy Before and After Surgery for Stage II,III Esophageal Squamous Cell Carcinoma | terminated | Phase 3 | 330 | Japan Clinical Oncology GroupOTHER | 1 | Sep 22, 2016 | clinicaltrials |
| NCT00920153 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | terminated | Phase 3 | 442 | French Innovative Leukemia OrganisationOTHER | 1 | Sep 16, 2016 | clinicaltrials |
| NCT00190476 | Elderly NSCLC/D vs DP (JCOG0207) | terminated | Phase 3 | 230 | Japan Clinical Oncology GroupOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | terminated | Phase 3 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT00004933 | Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | terminated | Phase 3 | 5 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00072215 | Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors | terminated | Phase 3 | 1 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 4, 2016 | clinicaltrials |
| NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC(Galaxy 2) | terminated | Phase 3 | 696 | Synta Pharmaceuticals Corp.INDUSTRY | 20 | Jul 1, 2016 | clinicaltrials |
| NCT01233544 | Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases(RAS01) | terminated | Phase 3 | 300 | University of AarhusOTHER | 2 | May 12, 2016 | clinicaltrials |
| NCT01981707 | F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer(PRECHOL) | terminated | Phase 2 / Phase 3 | 12 | University Hospital, GrenobleOTHER | 1 | Apr 28, 2016 | clinicaltrials |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy for Treatment of Locally Advanced Head and Neck Cancer | terminated | Phase 3 | 5 | BioVex LimitedINDUSTRY | 2 | Feb 8, 2016 | clinicaltrials |
| NCT00998738 | Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer | terminated | Phase 3 | 1 | Mayo ClinicOTHER | 1 | Feb 4, 2016 | clinicaltrials |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of Patients With Small Cell Lung Cancer and Extensive Disease (SCLC-ED) | terminated | Phase 3 | 281 | Danish Oncological Lung Cancer GroupOTHER | 1 | Jan 26, 2016 | clinicaltrials |
| NCT00345059 | The DISTAL-2 Study: Docetaxel Alone or in Combination in Second-line Treatment of Advanced Non Small-Cell Lung Cancer(DISTAL-2) | terminated | Phase 3 | 84 | National Cancer Institute, NaplesOTHER | 1 | Jan 14, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2018source: clinicaltrials